Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques.

Khanna M, Jackson RJ, Alcantara S, Amarasena TH, Li Z, Kelleher AD, Kent SJ, Ranasinghe C.

Sci Rep. 2019 Apr 5;9(1):5661. doi: 10.1038/s41598-019-41506-5.

2.

Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.

Ranasinghe C, Medveczky JC, Woltring D, Gao K, Thomson S, Coupar BE, Boyle DB, Ramsay AJ, Ramshaw IA.

Vaccine. 2006 Jul 26;24(31-32):5881-95. Epub 2006 May 2.

PMID:
16759767
3.

Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.

Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Montefiori DC, Carville A, Aldovini A.

J Virol. 2013 Apr;87(8):4738-50. doi: 10.1128/JVI.03531-12. Epub 2013 Feb 13.

4.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.

5.

Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.

Jackson RJ, Worley M, Trivedi S, Ranasinghe C.

Vaccine. 2014 Sep 29;32(43):5703-14. doi: 10.1016/j.vaccine.2014.08.023. Epub 2014 Aug 20.

6.

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, Kent SJ.

J Virol. 2007 Jan;81(1):292-300. Epub 2006 Oct 18.

7.

Early T Follicular Helper Cell Responses and Germinal Center Reactions Are Associated with Viremia Control in Immunized Rhesus Macaques.

Helmold Hait S, Vargas-Inchaustegui DA, Musich T, Mohanram V, Tuero I, Venzon DJ, Bear J, Rosati M, Vaccari M, Franchini G, Felber BK, Pavlakis GN, Robert-Guroff M.

J Virol. 2019 Feb 5;93(4). pii: e01687-18. doi: 10.1128/JVI.01687-18. Print 2019 Feb 15.

PMID:
30463978
8.

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Wilson KM, Ramsay AJ.

Vaccine. 2005 Oct 10;23(42):5009-21.

PMID:
15985317
9.

Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.

Jensen K, Nabi R, Van Rompay KKA, Robichaux S, Lifson JD, Piatak M Jr, Jacobs WR Jr, Fennelly G, Canfield D, Mollan KR, Hudgens MG, Larsen MH, Amedee AM, Kozlowski PA, De Paris K.

J Virol. 2016 Jul 27;90(16):7285-7302. doi: 10.1128/JVI.00481-16. Print 2016 Aug 15.

10.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

11.

Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara.

Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Montefiori DC, Mansfield KG, Carville A, Aldovini A.

J Immunol. 2011 Mar 15;186(6):3581-93. doi: 10.4049/jimmunol.1002594. Epub 2011 Feb 11.

12.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.

J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08. Epub 2008 Oct 29.

13.

Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.

Iyer SS, Gangadhara S, Victor B, Shen X, Chen X, Nabi R, Kasturi SP, Sabula MJ, Labranche CC, Reddy PB, Tomaras GD, Montefiori DC, Moss B, Spearman P, Pulendran B, Kozlowski PA, Amara RR.

J Virol. 2016 Sep 12;90(19):8842-54. doi: 10.1128/JVI.01163-16. Print 2016 Oct 1.

14.

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Manrique M, Micewicz E, Kozlowski PA, Wang SW, Aurora D, Wilson RL, Ghebremichael M, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):505-19. doi: 10.1089/aid.2007.0191.

15.

Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.

Manrique M, Kozlowski PA, Wang SW, Wilson RL, Micewicz E, Montefiori DC, Mansfield KG, Carville A, Aldovini A.

Mucosal Immunol. 2009 Nov;2(6):536-50. doi: 10.1038/mi.2009.103. Epub 2009 Sep 9.

PMID:
19741603
16.

Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.

Kasturi SP, Kozlowski PA, Nakaya HI, Burger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL, Kilgore KM, Johnson MJ, Nabi R, Legere T, Sher ZJ, Chen X, Amara RR, Hunter E, Bosinger SE, Spearman P, Crotty S, Villinger F, Derdeyn CA, Wrammert J, Pulendran B.

J Virol. 2017 Jan 31;91(4). pii: e01844-16. doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.

17.

Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.

Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, Yu L, Guan Y, Shen X, Tomaras GD, LaBranche C, Montefiori DC, Irene C, Prattipati R, Pinter A, Sullivan SM, Pavlakis GN, Felber BK.

Hum Vaccin Immunother. 2013 Oct;9(10):2069-80. doi: 10.4161/hv.25442. Epub 2013 Jul 2.

18.

Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge.

Mattapallil JJ, Hill B, Douek DC, Roederer M.

J Med Primatol. 2006 Aug;35(4-5):217-24.

PMID:
16872285
19.

A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA, Ramsay AJ.

Vaccine. 2011 Apr 5;29(16):3008-20. doi: 10.1016/j.vaccine.2011.01.106. Epub 2011 Feb 23.

20.

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, Moss B, Rose NF, Rose JK, Kozlowski PA, Abel K.

Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.

Supplemental Content

Support Center